/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Hisashi Hasumi

Yokohama City University Hospital(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

153

Papers

2.6K

Citations

24

h-index

52

i10-index

Hisashi Hasumi is an academic researcher from Yokohama City University Hospital. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Prostate Cancer Treatment and Research. The author has an h-index of 24, co-authored 131 publications.

ORCID: 0000-0001-8211-8835

Research Topics

Renal cell carcinoma treatment Renal and related cancers Prostate Cancer Treatment and Research Bladder and Urothelial Cancer Treatments Prostate Cancer Diagnosis and Treatment

Papers by this author

works

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

2024 · Journal of Clinical Oncology · 137 citations

https://doi.org/10.1200/jco.23.01569

Robert J. Motzer Camillo Porta Masatoshi Eto Thomas Powles

FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

2016 · BMC Cancer · 58 citations

https://doi.org/10.1186/s12885-016-2097-4

Noboru Nakaigawa Keiichi Kondo Ukihide Tateishi Ryogo Minamimoto

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer

2018 · BMC Urology · 58 citations

https://doi.org/10.1186/s12894-018-0414-8

Takashi Kawahara Yukari Ishiguro Shinji Ohtake Ikuma Kato

Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab

2019 · BMC Cancer · 25 citations

https://doi.org/10.1186/s12885-019-5510-y

Tadashi Tabei Noboru Nakaigawa Tomohiro Kaneta Ichiro Ikeda

Blood and lymphatic systems are segregated by the FLCN tumor suppressor

2020 · Nature Communications · 23 citations

https://doi.org/10.1038/s41467-020-20156-6

Ikue Tai-Nagara Yukiko Hasumi Dai Kusumoto Hisashi Hasumi

Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming

2024 · Cancer Science · 9 citations

https://doi.org/10.1111/cas.16243

Taisuke Akimoto Md. Rafikul Islam Akane Nagasako Kazuhito Kishi

Research topics

topics

Renal cell carcinoma treatment

Renal and related cancers

Prostate Cancer Treatment and Research

Bladder and Urothelial Cancer Treatments

Prostate Cancer Diagnosis and Treatment

Chat about Author

Papers

Chat

Click to start Chat